Search Result

Isoforms Recommended:	TXA₂/TP

Results for "

TXA 2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (2) COX (5) Endogenous Metabolite (3) Isotope-Labeled Compounds (2) Leukotriene Receptor (2) NF-κB (1) p38 MAPK (1) Phospholipase (1) Prostaglandin Receptor (44) Reference Standards (4) ROCK (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (38) Endocrinology (14) Inflammation/Immunology (14) Metabolic Disease (3) Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108566

U-46619 Maximum Cited Publications 11 Publications Verification 9,11-Methanoepoxy PGH2	Prostaglandin Receptor	Cardiovascular Disease
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-113350

Thromboxane A2 TXA2	Prostaglandin Receptor Endogenous Metabolite	Inflammation/Immunology Endocrinology Cancer
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .

HY-106105

ONO 3708	Prostaglandin Receptor	Others
ONO 3708 is a TXA₂/PGH₂ receptor antagonist that can inhibit the binding properties of U46619 in unactivated intact human platelets, with an IC₅₀ value of 38 nM .

HY-118044

I-SAP	Prostaglandin Receptor	Cardiovascular Disease
I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC) .

HY-101606

Etersalate Eterylate; Etherylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.

HY-101700

LCB-2853	Prostaglandin Receptor	Cardiovascular Disease
LCB-2853 is an antagonist of *thromboxane A2 (TXA2) receptor*, with antiplatelet and antithrombotic activities.

HY-118920

SQ 26655	Prostaglandin Receptor	Cardiovascular Disease
SQ 26655 is a TxA₂ receptor agonist. SQ 26655 induces human platelet aggregation .

HY-176022

U-46619 serinol amide	Prostaglandin Receptor	Cardiovascular Disease
U-46619 serinol amide is a derivative of U-46619 (HY-108566). U-46619 serinol amide is a stable analog of Thromboxane A2 (HY-113350) (TXA2). U-46619 serinol amide is a potent *TXA2* agonist that can induce platelet shape change and aggregation .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-121720

L 657925	Prostaglandin Receptor	Cardiovascular Disease
L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca2 ²⁺] .

HY-U00355

YM158 free base YM-57158	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
YM158 free base is a potent and selective LTD₄ and TXA₂ receptor antagonist with pA₂ values of about 8.87 and 8.81, respectively.

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

HY-169803

L-657926	Prostaglandin Receptor	Cardiovascular Disease
L-657926 is a stereoselective antagonist of the thromboxane A2 (TxA2) receptor, composed of (-)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid and (+)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-l-yl acetic acid. The IC₅₀s of (-) and (+) configurations for TxA2 are 0.27 nM and 124 nM, respectively.

HY-100570

KF15766	Prostaglandin Receptor	Inflammation/Immunology
KF15766 (compd 34E) is an orally active *TXA₂* and H₁ dual antagonist with K_is of 740 and 20 nM. KF15766 can be used for antiallergic research .

HY-B0428BR

Ozagrel hydrochloride (Standard) OKY-046 hydrochloride (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-N0607

Ginsenoside Ro 1 Publications Verification Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca ²⁺-antagonistic antiplatelet effect with an IC₅₀ of 155 μM. Ginsenoside Ro reduces the production of *TXA₂* more than it reduces the activities of COX-1 and TXAS.

HY-B0745

Ramatroban BAY u3405	Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban is a selective thromboxane A₂ (TxA₂, IC₅₀=14 nM) antagonist, which also antagonizes CRTH2 (IC₅₀=113 nM) by inhibiting PGD₂ binding.

HY-19249

Z-335 sodium	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Z-335 sodium is an orally active *thromboxane a₂ (TXA₂)* receptor antagonist, with IC₅₀** values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively .

HY-100283

CGS 15435	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CGS 15435, a potent thromboxane (TxA₂) synthetase inhibitor with an IC₅₀ of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI₂ synthetase and lipoxygenase enzymes.

HY-106066

Dazmegrel UK38485	Prostaglandin Receptor	Cardiovascular Disease
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .

HY-B0428D

(E/Z)-Ozagrel sodium (E/Z)-OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
(E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-18763A

Indobufen sodium Ibustrin sodium	COX	Cardiovascular Disease
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .

HY-18763

Indobufen 1 Publications Verification Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of *thromboxane A2 (TXA2) synthase* and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-121018

Daltroban BM-13505; SKF 96148	Prostaglandin Receptor	Cardiovascular Disease
Daltroban (BM-13505) is a selective and specific *thromboxane A2 (TXA2) receptor* antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-B0745S

Ramatroban-d4 BAY u3405-d₄	Isotope-Labeled Compounds Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-106080

Furegrelate U-63557A free acid	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate is being developed as an antiplatelet agent .

HY-158332

Sulotroban SKF-95587; BM-13177	Prostaglandin Receptor	Cardiovascular Disease
Sulotroban (SKF-95587; BM-13177) is a selective antagonist for thromboxane A2 receptor (TXA2 Receptor). Sulotroban exhibits inhibitory activity against carbocyclic thromboxane A2- and endoperoxide-induced vasoconstrictor. Sulotroban inhibits platelets aggregation .

HY-N0607R

Ginsenoside Ro (Standard) Polysciasaponin P3 (Standard); Chikusetsusaponin 5 (Standard); Chikusetsusaponin V (Standard)	Reference Standards Calcium Channel Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.

HY-16991

Terutroban 1 Publications Verification S-18886	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀0 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .

HY-18763S

Indobufen-d5 Ibustrin-d₅	Isotope-Labeled Compounds COX	Cardiovascular Disease
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-105120

Vapiprost GR 32191	Prostaglandin Receptor	Others
Vapiprost (GR 32191) is a *thromboxane A2 receptor (TXA2* Receptor) antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC₅₀** of less than 2.1×10 ^-8 M .

HY-126923

2,3-Dinor thromboxane B2 2,3-Dinor-TXB2	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
2,3-Dinor thromboxane B2 (2,3-Dinor-TXB2), a metabolite of urine, serves as an indicator of the production of thromboxane A2 (TxA2) in the body, and can be used as a tool to study the role of thromboxane in various pathophysiological processes in the human body .

HY-18763R

Indobufen (Standard) Ibustrin (Standard)	Reference Standards COX	Cardiovascular Disease
Indobufen (Standard) is the analytical standard of Indobufen. This product is intended for research and analytical applications. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-114846

Ro 22-9194	Prostaglandin Receptor	Cardiovascular Disease
Ro 22-9194 inhibits aggregation and thromboxane Az (TXA2) synthetase activity in rabbit and human platelets. Ro 22-9194 has a potent inhibitory action against various types of model arrhythmias. Ro 22-9194 has non-cholinergic cardiac depressant properties with its vasodilating action .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a *thromboxane A2 (TXA2) receptor* antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-130448

8-iso Prostaglandin F1β	Prostaglandin Receptor ROCK	Cardiovascular Disease
8-iso Prostaglandin F1β is an isoprostane, that exhibits vasoconstrictive effect in neonatal porcine pulmonary arteries, pulmonary veins, and mesenteric arteries. 8-iso Prostaglandin F1β targets TXA2 receptor and exhibits the blood vessel contractile efficacy under the influence of tyrosine kinase and Rho kinase .

HY-14654B

Aspirin DL-lysine Acetylsalicylic acid DL-lysine; ASA DL-lysine	COX NF-κB p38 MAPK	Cardiovascular Disease Others Inflammation/Immunology
Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .

HY-106080AR

Furegrelate sodium (Standard) U-63557A (Standard)	Prostaglandin Receptor Reference Standards	Cardiovascular Disease
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

HY-W612338

9-Oxononanoic acid 9-ONA	Phospholipase Prostaglandin Receptor	Cardiovascular Disease
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .

HY-105218A

Ifetroban sodium 1 Publications Verification BMS-180291 sodium	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-105218

Ifetroban 1 Publications Verification BMS-180291	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-16991R

Terutroban (Standard)	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Terutroban (Standard) is the analytical standard of Terutroban. This product is intended for research and analytical applications. Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC500 of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses antiatherosclerotic and antivasoconstrictor properties .

HY-137555

11-dehydro-2,3-dinor Thromboxane B2 11-dehydro-2,3-dinor TXB2	Endogenous Metabolite	Metabolic Disease
11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.

HY-135447

BM-531	Prostaglandin Receptor	Others
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Type

HY-135447

BM-531

Cell Assay Reagents

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Category	Target	Chemical Structure